Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xience Prime time

This article was originally published in The Gray Sheet

Executive Summary

Abbott receives CE mark approval for the next-generation everolimus-eluting coronary stent, clearing the way for a European market launch in the third quarter, the firm says June 23. Xience Prime uses the same drug and biocompatible polymer as Abbott's market-leading Xience V stent, available in the U.S. and Europe, but has a novel design and modified delivery system for greater flexibility and improved deliverability, the company says (1"The Gray Sheet" July 7, 2008). Xience Prime will be available in a broad range of sizes, including Prime SV for small vessels and Prime LL for long lesions
Advertisement

Related Content

Research In Brief
Xience V / Promus Drug-Eluting Stent Is Off And Running On U.S. Market
Xience V / Promus Drug-Eluting Stent Is Off And Running On U.S. Market

Topics

Advertisement
UsernamePublicRestriction

Register

MT027614

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel